The global diabetic macular edema market size accounted for USD 4,126 million in 2024 and is expected to exceed around USD 4,695 million by 2034, growing at a CAGR of 1.3% from 2024 to 2034.
With the growing prevalence of diabetes, particularly 2 diabetes, around the world, the occurrence of diabetic macular edema (DME) is rising. This is the most common retinal disorder resulting from high blood sugar levels that can lead to vision reduction or permanent blindness. The rising awareness about the early detection and prevention of DME among diabetic patients is a key factor driving the growth of the market. While there is no cure for DME, advancements in treatment options have made it possible to slow its progression and prevent blindness.
There is a high demand for effective therapeutic approaches, such as personalized treatments or gene therapy, which creates immense opportunities in the diabetic macular edema market. In addition, the increasing geriatric population contributes to market growth, as older people are more susceptible to diabetes. Due to the increasing instances of diabetic macular edema, North America is expected to sustain its market dominance in the near future. In addition, the availability of advanced therapeutic approaches due to its well-established healthcare system and rising healthcare expenditures support regional dominance.
Published by Laxmi Narayan
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
| Stats ID: | 7409 |
| Format: | Databook |
| Published: | January 2025 |
| Delivery: | Immediate |
| Stats ID: | 7409 |
| Format: | Databook |
| Published: | January 2025 |
| Delivery: | Immediate |
Unlock unlimited access to all exclusive market research reports, empowering your business.
Get industry insights at the most affordable plan
Stay ahead of the competition with comprehensive, actionable intelligence at your fingertips!
Learn More
Download
Actionable Solutions
